TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01225276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10%
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10%
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
Study: NCT01931150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dapsone 5% Gel
Study: NCT00269113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy
Description: As prescribed
Study: NCT01065506

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Cognitive Behavioral Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Cognitive Behavioral Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Nicotine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Nicotine Patch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Program
Description: Wellness Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic Exercise
Study: NCT02837796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transobturator tape

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transobturator tape
Study: NCT01931150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dapsone 5% Gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: The moisturizer for the study will be Vanicream™ Lite Lotion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: The moisturizer for the study will be Vanicream™ Lite Lotion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral antibiotics
Study: NCT03777085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2303
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
Study: NCT04123431

Intervention type: DEVICE
Intervention: Total Hip Replacement
Description: Primary elective total hip replacement

Intervention type: DEVICE
Intervention: Total Hip Replacement
Description: Primary elective total hip replacement

Intervention type: DEVICE
Intervention: Total Hip Replacement
Description: Primary elective total hip replacement
Study: NCT04593836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-menthol
Description: 20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Study: NCT04673812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL.
Study: NCT01628393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Oral capsule taken once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Oral capsule taken once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ozanimod
Description: Oral capsule taken once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule taken once a day
Study: NCT03742479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Silk
Description: Injectable Hyaluronic Acid (HA)
Study: NCT02012855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT04503850

Intervention type: DRUG
Intervention: Mirabegron 50 MG
Description: Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system

Intervention type: DRUG
Intervention: Alpha Blockers
Description: Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
Study: NCT02012855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet (meal type)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet (meal type)
Study: NCT01356498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg intravenous infusion
Study: NCT02931409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimal PEEP
Description: Optimal PEEP determined by Cstat during PEEP titration procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PEEP
Description: Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
Study: NCT01890590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
Study: NCT03311581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane inhalation 2\~4%
Study: NCT00511628

Intervention type: DRUG
Intervention: Risperidone
Description: As prescribed
Study: NCT02789436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L. reuteri Prodentis® lozenges
Description: Twice daily, for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: Twice daily, for 28 days
Study: NCT05525130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
Study: NCT02038777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ARA-C (LDAC)
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin given using 60 mg/m2 for 3-days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 100 mg/m2 on days 1 through 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
Study: NCT02323399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
Study: NCT04669691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
Study: NCT02219217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, Elvitegravir and Cobicistat
Study: NCT02425436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03578380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Lymphovenous anastomosis
Study: NCT02651779

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction and internal plate fixation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and plasterimmobilisation
Study: NCT04197427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse
Description: Experimental Oral Rinse is a proprietary formulation of GRAS ingredients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation without the active ingredients
Study: NCT03578380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression and drainage therapy
Description: Treatment with compression stockings and manual drainage (massage therapy)
Study: NCT00071799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Choice
Description: Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care
Study: NCT03661372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robot
Description: Use of a telesimulation robot using contextual interview format.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face
Description: Use of face-to-face patient interview using contextual interview format.
Study: NCT01692834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmune® Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSTAT®
Study: NCT01155960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study: NCT02038777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: PF-04449913 administered orally and continuously in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDAC
Description: Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
Study: NCT01432106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskerin/Valsartan and Rampiril
Description: Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskerin/Valsartan and Rampiril
Description: Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)
Study: NCT00391898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa/entacapone
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/carbidopa
Description: Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
Study: NCT00033423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT04569396

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemistry analysis
Description: Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: NAFLD fibrosis score
Description: NAFLD fibrosis score was determined among the study subjects before and after the surgery.

Intervention type: OTHER
Intervention: BMI measurement
Description: BMI was measured among the study subjects before and after the surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrosis 4 Index
Description: Fibrosis 4 Index was determined among the study subjects before and after the surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fatty Liver Index
Description: Fatty Liver Index was determined among the study subjects before and after the surgery.
Study: NCT01030653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole low dose
Description: Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole low dose
Description: Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole high dose
Description: Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole high dose
Description: Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
Study: NCT03240237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer SMART
Description: Cardiac Contractility Modulation
Study: NCT00977379

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
Study: NCT00033423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT01078194

Intervention type: DEVICE
Intervention: Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)
Description: Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
Study: NCT02452216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Undergo ferumoxytol-enhanced MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Analysis
Description: Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
Study: NCT02467192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose CT
Description: Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
Study: NCT03144336

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information provision
Description: All study participants will receive weekly messages with HIV prevention information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision
Description: All study participants will receive weekly messages with HIV prevention information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly quizzes
Description: Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
Study: NCT00977379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
Study: NCT03144336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewards for testing HIV-negative
Description: Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
Study: NCT04181229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.